June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
The LIMPIA Study: A randomized trial of supplementation with lutein, zeaxanthin, omega 3 fatty acids and antioxidants for increasing macular pigment optical density in high-risk subjects for exudative AMD.
Author Affiliations & Notes
  • Marie-Noelle Delyfer
    Ophthalmology, Hopital Pellegrin, Bordeaux, France
    Univ. Bordeaux, ISPED, Centre INSERM U897-Epidemiologie-Biostatistique, Bordeaux, France
  • Catherine P Garcher
    Ophthalmology CHU Dijon, Dijon, France
  • Marie B Rougier
    Ophthalmology, Hopital Pellegrin, Bordeaux, France
  • Hélène Savel
    CHU de Bordeaux, Pôle de Santé Publique, Unité de soutien méthodologique à la recherche clinique et épidémiologie (USMR), Bordeaux, France
  • Geneviève Chêne
    CHU de Bordeaux, Pôle de Santé Publique, Unité de soutien méthodologique à la recherche clinique et épidémiologie (USMR), Bordeaux, France
  • Cecile Delcourt
    Univ. Bordeaux, ISPED, Centre INSERM U897-Epidemiologie-Biostatistique, Bordeaux, France
    INSERM, ISPED, Centre INSERM U897-Epidemiologie-Biostatistique, Bordeaux, France
  • Jean-Francois Korobelnik
    Ophthalmology, Hopital Pellegrin, Bordeaux, France
    Univ. Bordeaux, ISPED, Centre INSERM U897-Epidemiologie-Biostatistique, Bordeaux, France
  • Footnotes
    Commercial Relationships Marie-Noelle Delyfer, Bayer (C), Carl Zeiss Meditec (C), Novartis (C), Thea (C); Catherine Garcher, None; Marie Rougier, Allergan (C), Bausch & Lomb (C), Bayer (C), Carl Zeiss Meditec (C), Novartis (C), Thea (C); Hélène Savel, None; Geneviève Chêne, None; Cecile Delcourt, Bausch & Lomb (C), Novartis (C), Thea (C); Jean-Francois Korobelnik, Alcon (C), Allergan (C), Bayer (C), Carl Zeiss Meditec (C), Horus (C), Novartis (C), Roche (C), Thea (C)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 3784. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Marie-Noelle Delyfer, Catherine P Garcher, Marie B Rougier, Hélène Savel, Geneviève Chêne, Cecile Delcourt, Jean-Francois Korobelnik; The LIMPIA Study: A randomized trial of supplementation with lutein, zeaxanthin, omega 3 fatty acids and antioxidants for increasing macular pigment optical density in high-risk subjects for exudative AMD.. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):3784. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: We performed a prospective randomized clinical trial testing the efficacy of a dietary supplement containing lutein, zeaxanthin, omega 3 fatty acids and antioxidants for increasing macular pigment density.

Methods: The Limpia Study is a double-blind, placebo-controlled, prospective randomized clinical trial performed in 120 subjects with at least one parent affected by neovascular AMD. Subjects were treated with placebo or active treatment during 6 months, and followed 6 months after the end of the treatment. The primary outcome was the variation of macular pigment optical density measured every 3 months during one year using two different techniques [modified HRA (Heidelberg) and Visucam 200 MPD (Carl Zeiss Meditec)].

Results: 120 subjects were included from January 2011 to January 2012 in 2 centers (Bordeaux and Dijon, France). Mean age was 56.7 years and 71.7 % were women. The mother of 97 subjects (80.8 %) was affected by AMD, while in only 25 subjects (20.8 %) the father was affected. Blood samples were collected and confirmed the increase of plasma carotenoids after 3 and 6 months of follow-up in the supplemented group, as compared to the placebo group. However, macular pigment measurements realized either using modified HRA (Heidelberg) or Visucam 200 MPD (Carl Zeiss Meditec) did not demonstrate any significant modifications in macular pigment optical density in the treated group as compared to the placebo group at any time of the study.

Conclusions: The LIMPIA randomized prospective clinical trial demonstrated an increase in plasma concentrations of both lutein and zeaxanthin after oral supplementation. However, it did not disclose any significant modification of macular pigment density after 6 months of oral supplementation in subjects with at least one parent affected by neovascular AMD. This can be explained either by defective carotenoid macular concentration in this high risk population for AMD and/or technical issues of the two quantification methods choosen for macular pigment measurments.<br />

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×